OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

Biogen Inc/  US09062X1037  /

NASDAQ
2024-11-06  10:00:00 PM Chg. -2.5300 Volume Bid1:52:54 AM Ask1:52:54 AM Market Capitalization Dividend Y. P/E Ratio
174.4000USD -1.43% 1.83 mill.
Turnover: 194.6 mill.		 173.6800Bid Size: 100 176.0000Ask Size: 500 25.41 bill.USD - 21.75
TeleTrader 10-30 US opens lower after earnings, jobs, GDP data
TeleTrader 10-30 Biogen's Q3 revenue down 3% to $2.5 billion
Newsfile Corp 10-10 SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to L...
GlobeNewswire 09-01 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...
GlobeNewswire 08-29 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...
GlobeNewswire 08-26 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...
GlobeNewswire 08-26 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 08-22 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire 08-19 Tiziana Life Sciences Appoints New Chief Executive Officer
GlobeNewswire 08-19 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...
GlobeNewswire 08-15 Soleno Therapeutics Announces Updates to its Board of Directors
GlobeNewswire 08-15 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire 08-08 Royalty Pharma Reports Second Quarter 2024 Results
GlobeNewswire 08-01 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
TeleTrader 08-01 Biogen books $2.5 billion in Q2 revenue
GlobeNewswire 08-01 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 07-31 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire 07-30 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...
GlobeNewswire 07-30 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...
GlobeNewswire 07-30 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...
GlobeNewswire 07-26 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...
GlobeNewswire 07-26 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
GlobeNewswire 07-26 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...
GlobeNewswire 07-22 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...
GlobeNewswire 07-22 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...